Centessa Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

MUN:260 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
20 Dec 24	Sell€920,695	Saurabh Saha	Individual	55,000	€16.74
16 Dec 24	Sell€149,708	Tia Bush	Individual	9,611	€15.58
16 Dec 24	Sell€1,118,983	Iqbal Hussain	Individual	71,705	€15.61
20 Nov 24	Sell€883,212	Saurabh Saha	Individual	55,000	€16.06
25 Oct 24	Sell€166,901	Gregory Weinhoff	Individual	11,742	€14.21
23 Oct 24	Sell€801,107	Saurabh Saha	Individual	55,000	€14.66
25 Sep 24	Sell€233,661	Gregory Weinhoff	Individual	16,619	€14.06

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 260?
Owner Type	Number of Shares	Ownership Percentage
State or Government	0	0%
Private Companies	27,500	0.0243%
Individual Insiders	2,231,979	1.97%
Hedge Funds	5,714,404	5.04%
General Public	14,577,636	12.9%
VC/PE Firms	39,606,764	35%
Institutions	51,156,012	45.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.3%.

Top Shareholders

Top 25 shareholders own 81.36% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
17.6%	Medicxi Ventures (UK) LLP	19,963,157	€220.9m	0%	60.51%
8.79%	Index Ventures SA	9,961,789	€110.2m	0%	9.55%
8.54%	General Atlantic Service Company, L.P.	9,681,818	€107.1m	0%	2.07%
5.04%	EcoR1 Capital, LLC	5,714,404	€63.2m	1.7%	2.05%
4.22%	First Light Asset Management, LLC	4,780,560	€52.9m	59.2%	4.69%
3.85%	T. Rowe Price Group, Inc.	4,364,366	€48.3m	47.5%	no data
3.47%	Perceptive Advisors LLC	3,933,307	€43.5m	27.6%	1.17%
3.47%	Vida Ventures Advisors, LLC	3,931,818	€43.5m	0%	35.1%
2.76%	Adage Capital Management, L.P.	3,125,000	€34.6m	38.9%	0.07%
2.55%	TCG Crossover Management, LLC	2,890,816	€32.0m	41.7%	3.57%
2.46%	FMR LLC	2,787,194	€30.8m	0%	no data
2.07%	Octagon Capital Advisors LP	2,345,075	€25.9m	13.8%	4.4%
1.86%	Artal Group S.A.	2,112,500	€23.4m	49.6%	0.6%
1.85%	Driehaus Capital Management LLC	2,092,011	€23.1m	89.5%	0.17%
1.81%	Morgan Stanley, Investment Banking and Brokerage Investments	2,049,548	€22.7m	-4.09%	no data
1.76%	Farallon Capital Management, L.L.C.	1,996,000	€22.1m	438%	0.16%
1.58%	Point72 Asset Management, L.P.	1,788,077	€19.8m	-23.3%	0.05%
1.42%	Cormorant Asset Management, LP	1,611,600	€17.8m	187%	1.08%
1.1%	5AM Venture Management, LLC	1,245,000	€13.8m	0%	3.29%
1.02%	Franklin Resources, Inc.	1,156,723	€12.8m	0%	0.01%
1%	Affinity Asset Advisors, LLC	1,135,702	€12.6m	36.7%	2.38%
0.9%	Balyasny Asset Management L.P.	1,023,122	€11.3m	302%	0.03%
0.83%	American Century Investment Management Inc	935,151	€10.3m	1.3%	0.01%
0.77%	David Grainger	870,190	€9.6m	0.61%	no data
0.61%	Tanager Wealth Management LLP	696,096	€7.7m	0%	1.26%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/08/20 08:48
End of Day Share Price	2024/05/24 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Centessa Pharmaceuticals plc is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	BMO Capital Markets Equity Research
Konstantinos Biliouris	BMO Capital Markets Equity Research
Mayank Mamtani	B. Riley Securities, Inc.